THERAPEUTIC AREAS Archives - Page 29 of 32

Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase

Structure-based design was utilized to optimize 6,6-diaryl substituted dihydropyrone and hydroxylactam to obtain inhibitors of lactate dehydrogenase (LDH) with low...

HIJACKING CELLULAR MECHANISMS TO TREAT COMPLEX DISEASES

RARE DISEASES: OPPORTUNITIES AND CHALLENGES FOR TREATMENTS DELIVERED BY ADENO-ASSOCIATED VIRUSES

Brain metastasis mouse models for the evaluation of multikinase inhibitors on ROS1-fusion-positive lung cancer

Lung cancer is the leading cause of cancer-related death worldwide. Nearly 80% of lung cancers are non-small cell lung cancer...

Intra-carotid artery brain metastasis models for the evaluation of lung and breast cancer drugs

Non-CNS metastatic brain cancer is approximately 10 times more common than CNS cancer. Lung cancer and breast cancer account for...

Developing drug-induced resistant tumor models for efficacy evaluation of next-generation anticancer therapies

The therapeutic landscape of cancer has been transformed over the last few decades. Our understanding of cancer and its therapeutic...

Developing a panel of orthotopic syngeneic tumor models for IO drug discovery

The efficacy of immuno-oncology therapies needs to be evaluated in animal models with functional immune systems. Syngeneic tumor models are...

Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery

We have established an advanced and integrated in vitro and in vivo platform for various types of cancer vaccines, including...

Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of the DNA damage response

Ionizing radiation has largely been recognized as a local targeted therapy by a variety of mechanisms, including inducing direct DNA...

Knowledge Library